141A — Trial Holdings Income Statement
0.000.00%
- ¥339bn
- ¥273bn
- ¥655bn
- 87
- 54
- 62
- 81
Annual income statement for Trial Holdings, fiscal year end - June 30th, JPY millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | JAS | JAS | JAS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 157,934 | 597,689 | 655,478 |
Cost of Revenue | |||
Gross Profit | 29,060 | 112,273 | 127,637 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 156,494 | 586,332 | 641,835 |
Operating Profit | 1,440 | 11,357 | 13,643 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 2,489 | 12,029 | 14,067 |
Provision for Income Taxes | |||
Net Income After Taxes | 1,960 | 7,560 | 8,473 |
Minority Interest | |||
Net Income Before Extraordinary Items | |||
Net Income | 1,847 | 7,136 | 8,086 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 1,846 | 7,135 | 8,084 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 19.5 | 63.9 | 69.8 |
Dividends per Share |